Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 33,720 articles published since 2008
|||| 19 

These are the 33720 published articles about Melanoma that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
51 Guideline Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008

Dummer, R / Hauschild, A / Jost, L / Anonymous3710598. ·Department of Dermatology, University of Kiel, Kiel, Germany. ·Ann Oncol · Pubmed #18456782.

ABSTRACT: -- No abstract --

52 Guideline Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. 2008

Garbe, Claus / Hauschild, Axel / Volkenandt, Matthias / Schadendorf, Dirk / Stolz, Wilhelm / Reinhold, Uwe / Kortmann, Rolf-Dieter / Kettelhack, Christoph / Frerich, Bernhard / Keilholz, Ulrich / Dummer, Reinhard / Sebastian, Günther / Tilgen, Wolfgang / Schuler, Gerold / Mackensen, Andreas / Kaufmann, Roland. ·University Department of Dermatology, Tübingen, Germany. claus.garbe@med.uni-tuebingen.de ·Melanoma Res · Pubmed #18337653.

ABSTRACT: Systemic medical treatment of melanoma is administered in the adjuvant and palliative setting. Adjuvant therapy may be considered in patients with primary melanoma with more than 1.5 mm tumor thickness and with regional node metastasis. Presently no indication for systemic adjuvant chemotherapy or for adjuvant therapy with nonspecific immune-stimulatory agents outside controlled studies is seen. Interferon-alpha is the first substance in the adjuvant therapy of melanoma, which has shown to present a significant advantage to the patients in some prospective randomized studies. Good arguments for using adjuvant interferon-alpha therapy in high-risk melanoma patients exist. Both high-dose and low-dose interferon-alpha show promise. The major indications for systemic chemotherapy and chemoimmunotherapy are inoperable recurrent tumors, inoperable regional metastases and distant metastases (stage IV). As treatment in such situations is primarily palliative, the effect of any regimen on the quality of life must be carefully weighed. As a first line treatment, single agent therapy is recommended, as polychemotherapy or biochemotherapy did not show significant advantages for prolongation of survival; hence they are more toxic. An urgent need for development of new treatment modalities is necessary and general principles of experimental immunotherapy are outlined.

53 Guideline Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. 2008

Garbe, Claus / Hauschild, Axel / Volkenandt, Matthias / Schadendorf, Dirk / Stolz, Wilhelm / Reinhold, Uwe / Kortmann, Rolf-Dieter / Kettelhack, Christoph / Frerich, Bernhard / Keilholz, Ulrich / Dummer, Reinhard / Sebastian, Günther / Tilgen, Wolfgang / Schuler, Gerold / Mackensen, Andreas / Kaufmann, Roland. ·University Department of Dermatology, Tübingen, Germany. claus.garbe@med.uni-tuebingen.de ·Melanoma Res · Pubmed #18227710.

ABSTRACT: The primary treatment of a melanoma is surgical excision. An excisional biopsy is preferred, and safety margins of 1 cm for tumor thickness up to 2 mm and 2 cm for higher tumor thickness should be applied either at primary excision or in a two-step procedure. When dealing with facial, acral or anogenital melanomas, micrographic control of the surgical margins may be preferable to allow reduced safety margins and conservation of tissue. The sentinel lymph node biopsy should be performed in patients whose primary melanoma is thicker than 1.0 mm and this operation should be performed in centers where both the operative and nuclear medicine teams are experienced. In clinically identified lymph node metastases, radical lymph node dissection is considered standard therapy. If distant metastases involve just one internal organ and operative removal is feasible, then surgery should be seen as therapy of choice. Radiation therapy for the primary treatment of melanoma is indicated only in those cases in which surgery is impossible or not reasonable. In regional lymph nodes, radiation therapy is usually recommended when excision is not complete (R1 resection) or if the nodes are inoperable. In distant metastases, radiation therapy is particularly indicated in bone metastases, brain metastases and soft tissue metastases.

54 Editorial The role of sunscreen in the prevention of cutaneous melanoma and nonmelanoma skin cancer. 2019

Waldman, Reid A / Grant-Kels, Jane M. ·Dermatology Department, University of Connecticut Health Center, Farmington, Connecticut. · Dermatology Department, University of Connecticut Health Center, Farmington, Connecticut. Electronic address: grant@uchc.edu. ·J Am Acad Dermatol · Pubmed #30012373.

ABSTRACT: -- No abstract --

55 Editorial Screening for melanoma is a poor idea. 2018

Bretthauer, Michael. · ·Tidsskr Nor Laegeforen · Pubmed #30378406.

ABSTRACT: -- No abstract --

56 Editorial Is Collaborative Ocular Melanoma Study (COMS) still relevant? 2018

Honavar, Santosh G. ·Editor, Indian Journal of Ophthalmology, Editorial Office: Centre for Sight, Road No. 2, Banjara Hills, Hyderabad 500034, Telangana, India. ·Indian J Ophthalmol · Pubmed #30249817.

ABSTRACT: -- No abstract --

57 Editorial Immunotherapy for Melanoma Metastatic to the Brain. 2018

Turajlic, Samra / Larkin, James. ·From the Renal and Skin Units, Royal Marsden NHS Foundation Trust (S.T., J.L.), and the Translational Cancer Therapeutics Laboratory, Francis Crick Institute (S.T.) - both in London. ·N Engl J Med · Pubmed #30134137.

ABSTRACT: -- No abstract --

58 Editorial Coned Radial Forearm Free Flap for Improved Retention of Orbital Prosthesis following Orbital Exenteration. 2018

Zhou, Kiane / Luong, Jason K / Clark, Jonathan R / Ch'ng, Sydney. ·Royal Prince Alfred Hospital Westmead Clinical School, Westmead and, Institute of Academic Surgery, Royal Prince Alfred Hospital, University of Sydney Institute of Academic Surgery, Royal Prince Alfred Hospital, University of Sydney and Department of Head and Neck Surgery, Chris O'Brien Lifehouse Cancer Centre Institute of Academic Surgery, Royal Prince Alfred Hospital, University of Sydney, Department of Head and Neck Surgery, Chris O'Brien Lifehouse Cancer Centre, and Department of Plastic Surgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. ·Plast Reconstr Surg · Pubmed #30119127.

ABSTRACT: -- No abstract --

59 Editorial When is surgery for metastatic melanoma still the most appropriate treatment option? 2018

Friedman, Erica B / Ferguson, Peter M / Thompson, John F. ·a Melanoma Institute Australia , The University of Sydney , North Sydney , Australia. · b Department of Tissue Pathology and Diagnostic Oncology , Royal Prince Alfred Hospital , Camperdown , Australia. · d The Faculty of Medicine and Health , The University of Sydney , Sydney , NSW , Australia. · c Department of Melanoma and Surgical Oncology , Royal Prince Alfred Hospital , Camperdown , NSW , Australia. ·Expert Rev Anticancer Ther · Pubmed #30071762.

ABSTRACT: -- No abstract --

60 Editorial MelMART Trial: It's Now or Never. 2018

Coit, Daniel / Ariyan, Charlotte. ·Memorial Sloan Kettering Cancer Center, New York, USA. · Memorial Sloan Kettering Cancer Center, New York, USA. ariyanc@mskcc.org. ·Ann Surg Oncol · Pubmed #29946999.

ABSTRACT: -- No abstract --

61 Editorial Where are all the women scientists in pigment cell and melanoma research? 2018

Setaluri, Vijayasaradhi. ·Department of Dermatology, University of Wisconsin-Madison, Madison, WI, USA. ·Pigment Cell Melanoma Res · Pubmed #29927547.

ABSTRACT: -- No abstract --

62 Editorial A step toward demystifying melanomas of unknown primary sites. 2018

Heymann, Warren R. ·Division of Dermatology, Cooper Medical School of Rowan University, Marlton, New Jersey. Electronic address: wrheymann@gmail.com. ·J Am Acad Dermatol · Pubmed #29857013.

ABSTRACT: -- No abstract --

63 Editorial Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. 2018

Gershenwald, Jeffrey E / Scolyer, Richard A. ·Departments of Surgical Oncology and Cancer Biology, Unit 1484, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jgershen@mdanderson.org. · Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jgershen@mdanderson.org. · Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. · Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. · Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. ·Ann Surg Oncol · Pubmed #29850954.

ABSTRACT: -- No abstract --

64 Editorial Recent breakthroughs in metastatic uveal melanoma: a cause for optimism? 2018

Sacco, Joseph J / Kalirai, Helen / Kenyani, Jenna / Figueiredo, Carlos R / Coulson, Judy M / Coupland, Sarah E. ·Liverpool Ocular Oncology Research Group, Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK. · Department of Medical Oncology, Clatterbridge Cancer Centre, Bebington, UK. · Department of Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, UK. · Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, UK. ·Future Oncol · Pubmed #29741103.

ABSTRACT: -- No abstract --

65 Editorial A new era of proactive melanoma therapy: hit hard, hit early. 2018

Haas, L / Wiesner, T / Obenauf, A C. ·Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Campus-Vienna-Biocenter 1, 1030, Vienna, Austria. · Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna,, Austria. ·Br J Dermatol · Pubmed #29668089.

ABSTRACT: -- No abstract --

66 Editorial Commentary: Moving beyond surveys to assess patient preferences. 2018

Perlis, Clifford S. ·Keystone Dermatology Partners, King of Prussia, Pennsylvania. Electronic address: cperlis@keyderm.com. ·J Am Acad Dermatol · Pubmed #29627337.

ABSTRACT: -- No abstract --

67 Editorial Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage. 2018

Taylor, Kristin N / Schlaepfer, David D. ·Department of Reproductive Medicine, University of California, San Diego, School of Medicine, Moores Cancer Center, La Jolla, California. · Department of Reproductive Medicine, University of California, San Diego, School of Medicine, Moores Cancer Center, La Jolla, California. dschlaepfer@ucsd.edu. ·Mol Cancer Ther · Pubmed #29610281.

ABSTRACT: Oncogenes provide tumor cells with a growth and survival advantage. Directed therapies targeted to oncogenic mutations (such as

68 Editorial ECCO essential requirements for quality cancer care for melanoma: Defining how to organise care. 2018

Wouters, Michel W. ·with responsibility for ECCO ERQCC Melanoma Working Group, Department of Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: M.Wouters@nki.nl. ·Eur J Surg Oncol · Pubmed #29525468.

ABSTRACT: -- No abstract --

69 Editorial Prognostic features for acral lentiginous melanoma. 2018

Cust, A E. ·Sydney School of Public Health and Melanoma Institute Australia, The University of Sydney, Australia. ·Br J Dermatol · Pubmed #29441559.

ABSTRACT: -- No abstract --

70 Editorial Commentary: Skin cancer in the military. 2018

Wisco, Oliver J / Hajar, Tamar / Grande, Donald J. ·Department of Dermatology, Oregon Health and Science University, Portland, Oregon; Mystic Valley Dermatology, Stoneham, Massachusetts. Electronic address: wiscoj@gmail.com. · Department of Dermatology, Oregon Health and Science University, Portland, Oregon. · Mystic Valley Dermatology, Stoneham, Massachusetts. ·J Am Acad Dermatol · Pubmed #29438768.

ABSTRACT: -- No abstract --

71 Editorial How breakthroughs in translational research have impacted treatment strategies for melanoma. 2018

Verykiou, S / Edwards, N / Hill, D. ·Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K. ·Br J Dermatol · Pubmed #29357607.

ABSTRACT: -- No abstract --

72 Editorial A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma. 2018

Muthiah, S / Tang, D / Nasr, B / Verykiou, S. ·Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K. · Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle, U.K. · James Cook University Hospital, Middlesbrough, Teeside, U.K. ·Br J Dermatol · Pubmed #29357596.

ABSTRACT: -- No abstract --

73 Editorial Progress in the diagnosis and therapy of melanoma. 2018

Wiesner, T / Zbyszewski, A. ·Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. ·Br J Dermatol · Pubmed #29357589.

ABSTRACT: -- No abstract --

74 Editorial Sunscreen and melanoma prevention: evidence and expectations. 2018

Wehner, M R. ·Department of Dermatology, University of Pennsylvania, Philadelphia, PA, U.S.A. ·Br J Dermatol · Pubmed #29357579.

ABSTRACT: -- No abstract --

75 Editorial Malignant Melanoma: How Do We Meet the Needs of Young People and Their Families? 2018

McInally, Wendy. ·a Department of Nursing, School of Health and Social Care , Edinburgh Napier University , Edinburgh , Scotland, United Kingdom. ·Compr Child Adolesc Nurs · Pubmed #29351502.

ABSTRACT: -- No abstract --

Back · Next